{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T08:53:07Z","timestamp":1782636787568,"version":"3.54.5"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Guangdong Esophageal Cancer Institute Science and Technology Program","award":["M201715"],"award-info":[{"award-number":["M201715"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["(No.81874220)"],"award-info":[{"award-number":["(No.81874220)"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1245\/s10434-019-07334-7","type":"journal-article","created":{"date-parts":[[2019,4,30]],"date-time":"2019-04-30T06:10:29Z","timestamp":1556604629000},"page":"2882-2889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Treatment-Related Lymphopenia Predicts Pathologic Complete Response and Recurrence in Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy"],"prefix":"10.1245","volume":"26","author":[{"given":"Qiaoqiao","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiliang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songran","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengzhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mian","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"key":"7334_CR1","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P Hagen van","year":"2012","unstructured":"van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u201384.","journal-title":"N Engl J Med"},{"key":"7334_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S1470-2045(11)70142-5","volume":"12","author":"KM Sjoquist","year":"2011","unstructured":"Sjoquist KM, Burmeister BH, Smithers BM, et al. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12:681\u201392.","journal-title":"Lancet Oncol"},{"key":"7334_CR3","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","volume":"36","author":"H Yang","year":"2018","unstructured":"Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36:2796\u2013803.","journal-title":"J Clin Oncol"},{"key":"7334_CR4","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/SLA.0000000000002352","volume":"268","author":"M Xi","year":"2018","unstructured":"Xi M, Hallemeier CL, Merrell KW, et al. Recurrence risk stratification after preoperative chemoradiation of esophageal adenocarcinoma. Ann Surg. 2018;268:289\u201395.","journal-title":"Ann Surg"},{"key":"7334_CR5","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.ijrobp.2010.03.003","volume":"80","author":"RV Scheer","year":"2011","unstructured":"Scheer RV, Fakiris AJ, Johnstone PA. Quantifying the benefit of a pathologic complete response after neoadjuvant chemoradiotherapy in the treatment of esophageal cancer. Int J Radiat Oncol Biol Phys. 2011;80:996\u20131001.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7334_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/SLA.0000000000002670","author":"M Xi","year":"2018","unstructured":"Xi M, Yang Y, Zhang L, et al. Multi-institutional analysis of recurrence and survival after neoadjuvant chemoradiotherapy of esophageal cancer: impact of histology on recurrence patterns and outcomes. Ann Surg. 2018. \n                    https:\/\/doi.org\/10.1097\/SLA.0000000000002670\n                    \n                  .","journal-title":"Ann Surg"},{"key":"7334_CR7","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1093\/annonc\/mds210","volume":"23","author":"JA Ajani","year":"2012","unstructured":"Ajani JA, Correa AM, Hofstetter WL, et al. Clinical parameters model for predicting pathologic complete response following preoperative chemoradiation in patients with esophageal cancer. Ann Oncol. 2012;23:2638\u201342.","journal-title":"Ann Oncol"},{"key":"7334_CR8","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ijrobp.2013.09.037","volume":"88","author":"H Zhang","year":"2014","unstructured":"Zhang H, Tan S, Chen W, et al. Modeling pathologic response of esophageal cancer to chemoradiation therapy using spatial-temporal 18F-FDG PET features, clinical parameters, and demographics. Int J Radiat Oncol Biol Phys. 2014;88:195\u2013203.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7334_CR9","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.radonc.2015.04.028","volume":"115","author":"EL Toxopeus","year":"2015","unstructured":"Toxopeus EL, Nieboer D, Shapiro J, et al. Nomogram for predicting pathologically complete response after neoadjuvant chemoradiotherapy for oesophageal cancer. Radiother Oncol. 2015;115:392\u20138.","journal-title":"Radiother Oncol"},{"key":"7334_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1245\/s10434-015-4764-0","volume":"23","author":"SL Liu","year":"2016","unstructured":"Liu SL, Xi M, Yang H, et al. Is there a correlation between clinical complete response and pathological complete response after neoadjuvant chemoradiotherapy for esophageal squamous cell cancer? Ann Surg Oncol. 2016;23:273\u201381.","journal-title":"Ann Surg Oncol"},{"key":"7334_CR11","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djs629","volume":"105","author":"SC Formenti","year":"2013","unstructured":"Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst. 2013;105:256\u201365.","journal-title":"J Natl Cancer Inst"},{"key":"7334_CR12","doi-asserted-by":"publisher","first-page":"149","DOI":"10.2217\/cns.12.14","volume":"1","author":"S Yovino","year":"2012","unstructured":"Yovino S, Grossman SA. Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomas. CNS Oncol. 2012;1:149\u201354.","journal-title":"CNS Oncol"},{"key":"7334_CR13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.3109\/07357907.2012.700987","volume":"30","author":"A Balmanoukian","year":"2012","unstructured":"Balmanoukian A, Ye X, Herman J, et al. The association between treatment-related lymphopenia and survival in newly diagnosed patients with resected adenocarcinoma of the pancreas. Cancer Invest. 2012;30:571\u20136.","journal-title":"Cancer Invest"},{"key":"7334_CR14","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1016\/j.ijrobp.2014.04.025","volume":"89","author":"C Tang","year":"2014","unstructured":"Tang C, Liao Z, Gomez D, et al. Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014;89:1084\u201391.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7334_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4143\/crt.2016.595","volume":"50","author":"LT Liu","year":"2018","unstructured":"Liu LT, Chen QY, Tang LQ, et al. The prognostic value of treatment-related lymphopenia in nasopharyngeal carcinoma patients. Cancer Res Treat. 2018;50:19\u201329.","journal-title":"Cancer Res Treat"},{"key":"7334_CR16","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1002\/hed.23535","volume":"36","author":"JL Campian","year":"2014","unstructured":"Campian JL, Sarai G, Ye X, et al. Association between severe treatment-related lymphopenia and progression-free survival in patients with newly diagnosed squamous cell head and neck cancer. Head Neck. 2014;36:1747\u201353.","journal-title":"Head Neck"},{"key":"7334_CR17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.4143\/crt.2014.351","volume":"48","author":"J Heo","year":"2016","unstructured":"Heo J, Chun M, Noh OK, et al. Sustaining blood lymphocyte count during preoperative chemoradiotherapy as a predictive marker for pathologic complete response in locally advanced rectal cancer. Cancer Res Treat. 2016;48:232\u20139.","journal-title":"Cancer Res Treat"},{"key":"7334_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijrobp.2017.05.037","volume":"99","author":"R Davuluri","year":"2017","unstructured":"Davuluri R, Jiang W, Fang P, et al. Lymphocyte nadir and esophageal cancer survival outcomes after chemoradiation therapy. Int J Radiat Oncol Biol Phys. 2017;99:128\u201335.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"7334_CR19","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.radonc.2018.02.025","volume":"128","author":"P Fang","year":"2018","unstructured":"Fang P, Jiang W, Davuluri R, et al. High lymphocyte count during neoadjuvant chemoradiotherapy is associated with improved pathologic complete response in esophageal cancer. Radiother Oncol. 2018;128:584\u201390.","journal-title":"Radiother Oncol"},{"key":"7334_CR20","volume-title":"AJCC cancer staging manual","year":"2010","unstructured":"Edge SB, Byrd DR, Compton CC, et al. (eds). AJCC cancer staging manual. 7th ed. New York: Springer; 2010.","edition":"7"},{"key":"7334_CR21","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1245\/s10434-018-6736-7","volume":"25","author":"S Zhou","year":"2018","unstructured":"Zhou S, Liu S, Zhang L, et al. Recurrence risk based on pathologic stage after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma: implications for risk-based postoperative surveillance strategies. Ann Surg Oncol. 2018;25:3639\u201346.","journal-title":"Ann Surg Oncol"},{"key":"7334_CR22","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1097\/01.pas.0000213312.36306.cc","volume":"31","author":"TT Wu","year":"2007","unstructured":"Wu TT, Chirieac LR, Abraham SC, et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma: a reliable predictor for patient outcome. Am J Surg Pathol. 2007;31:58\u201364.","journal-title":"Am J Surg Pathol"},{"key":"7334_CR23","doi-asserted-by":"publisher","first-page":"90","DOI":"10.4103\/0973-1482.154081","volume":"12","author":"Y Sun","year":"2016","unstructured":"Sun Y, Cheng S, Lu Y, et al. The clinical efficacy of consolidation chemotherapy for resectable esophageal squamous cell cancer after trimodality therapy. J Cancer Res Ther. 2016;12:90\u20135.","journal-title":"J Cancer Res Ther"},{"key":"7334_CR24","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/SLA.0000000000001954","volume":"266","author":"BM Burt","year":"2017","unstructured":"Burt BM, Groth SS, Sada YH, et al. Utility of adjuvant chemotherapy after neoadjuvant chemoradiation and esophagectomy for esophageal cancer. Ann Surg. 2017;266:297\u2013304.","journal-title":"Ann Surg"},{"key":"7334_CR25","doi-asserted-by":"publisher","first-page":"140","DOI":"10.3109\/07357907.2012.762780","volume":"31","author":"S Yovino","year":"2013","unstructured":"Yovino S, Kleinberg L, Grossman SA, et al. The etiology of treatment-related lymphopenia in patients with malignant gliomas: modeling radiation dose to circulating lymphocytes explains clinical observations and suggests methods of modifying the impact of radiation on immune cells. Cancer Invest. 2013;31:140\u20134.","journal-title":"Cancer Invest"},{"key":"7334_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.radonc.2017.11.028","volume":"128","author":"Y Shiraishi","year":"2018","unstructured":"Shiraishi Y, Fang P, Xu C, et al. Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: a propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2018;128:154\u201360.","journal-title":"Radiother Oncol"},{"key":"7334_CR27","doi-asserted-by":"publisher","first-page":"4792","DOI":"10.1158\/1078-0432.CCR-13-0380","volume":"19","author":"MJ Besser","year":"2013","unstructured":"Besser MJ, Shapira-Frommer R, Itzhaki O, et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin Cancer Res. 2013;19:4792\u2013800.","journal-title":"Clin Cancer Res"},{"key":"7334_CR28","doi-asserted-by":"publisher","first-page":"e976507","DOI":"10.4161\/23723556.2014.976507","volume":"4","author":"J Li","year":"2015","unstructured":"Li J, Chen QY, He J, et al. Phase I trial of adoptively transferred tumor-infiltrating lymphocyte immunotherapy following concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma. Oncoimmunology. 2015;4:e976507.","journal-title":"Oncoimmunology"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07334-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-019-07334-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-019-07334-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,27]],"date-time":"2020-04-27T23:14:37Z","timestamp":1588029277000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-019-07334-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["7334"],"URL":"https:\/\/doi.org\/10.1245\/s10434-019-07334-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,29]]},"assertion":[{"value":"25 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}